Highstreet Asset Management Inc. raised its stake in Pfizer Inc. (NYSE:PFE) by 225.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 318,230 shares of the biopharmaceutical company’s stock after buying an additional 220,431 shares during the quarter. Pfizer comprises approximately 1.2% of Highstreet Asset Management Inc.’s investment portfolio, making the stock its 26th biggest holding. Highstreet Asset Management Inc.’s holdings in Pfizer were worth $10,694,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Janney Montgomery Scott LLC lifted its position in shares of Pfizer by 11.5% in the first quarter. Janney Montgomery Scott LLC now owns 1,800,922 shares of the biopharmaceutical company’s stock worth $61,610,000 after purchasing an additional 185,655 shares in the last quarter. Shell Asset Management Co. lifted its position in shares of Pfizer by 1.6% in the first quarter. Shell Asset Management Co. now owns 1,217,435 shares of the biopharmaceutical company’s stock worth $41,648,000 after purchasing an additional 19,646 shares in the last quarter. K.J. Harrison & Partners Inc lifted its position in shares of Pfizer by 11.9% in the first quarter. K.J. Harrison & Partners Inc now owns 48,639 shares of the biopharmaceutical company’s stock worth $1,664,000 after purchasing an additional 5,159 shares in the last quarter. iAB Financial Bank lifted its position in shares of Pfizer by 1.1% in the first quarter. iAB Financial Bank now owns 13,925 shares of the biopharmaceutical company’s stock worth $476,000 after purchasing an additional 157 shares in the last quarter. Finally, Moloney Securities Asset Management LLC increased its holdings in Pfizer by 10.3% during the first quarter. Moloney Securities Asset Management LLC now owns 27,478 shares of the biopharmaceutical company’s stock worth $940,000 after buying an additional 2,567 shares during the last quarter. 69.89% of the stock is currently owned by hedge funds and other institutional investors.
In other news, insider Sally Susman sold 38,230 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares of the company’s stock, valued at $5,097,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The disclosure for this sale can be found here. Insiders have sold 60,280 shares of company stock valued at $2,118,988 in the last ninety days. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc. (NYSE PFE) traded down $0.07 during mid-day trading on Wednesday, hitting $35.56. 17,379,124 shares of the company traded hands, compared to its average volume of 19,977,008. Pfizer Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market capitalization of $212,200.00, a P/E ratio of 14.42, a PEG ratio of 2.54 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter in the prior year, the business posted $0.61 earnings per share. Pfizer’s revenue was up .9% compared to the same quarter last year. equities research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. The ex-dividend date was Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.60%. Pfizer’s dividend payout ratio is 78.53%.
PFE has been the topic of a number of recent analyst reports. Cowen set a $43.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, August 14th. Jefferies Group set a $35.00 target price on shares of Pfizer and gave the stock a “neutral” rating in a report on Thursday, August 24th. Berenberg Bank restated a “hold” rating and set a $36.00 target price (down from $39.00) on shares of Pfizer in a report on Tuesday, August 15th. Deutsche Bank set a $38.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Goldman Sachs Group set a $36.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, November 1st. Two research analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.77.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://ledgergazette.com/2017/12/07/highstreet-asset-management-inc-increases-holdings-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.